Research programme: GPR65 modulators - Golgi Neurosciences
Latest Information Update: 25 Mar 2025
At a glance
- Originator Golgi Neurosciences
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action GPR65 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Fibrosis; Inflammation; Inflammatory bowel diseases; Multiple sclerosis; Parkinson's disease
Most Recent Events
- 18 Mar 2025 GPR65 modulators are available for licensing as of 18 Mar 2025. https://golgineurosciences.com/projects-for-partnering/ (Golgi Neurosciences pipeline, March 2025)
- 18 Mar 2025 Preclinical trials in Cancer in Italy (unspecified route), before March 2025 (Golgi Neurosciences pipeline, March 2025)
- 18 Mar 2025 Preclinical trials in Fibrosis in Italy (unspecified route), before March 2025 (Golgi Neurosciences pipeline, March 2025)